{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:32:46Z","timestamp":1783420366358,"version":"3.54.6"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5,1]]},"DOI":"10.1093\/jac\/dkl093","type":"journal-article","created":{"date-parts":[[2006,3,21]],"date-time":"2006-03-21T01:34:18Z","timestamp":1142904858000},"page":"914-923","source":"Crossref","is-referenced-by-count":24,"title":["Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003\u20132004)"],"prefix":"10.1093","volume":"57","author":[{"given":"Amy A.","family":"Watters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Leeds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,3,20]]},"reference":[{"key":"key\n\t\t\t\t20171010182121_B1","doi-asserted-by":"crossref","unstructured":"Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest2001; 119: 397S\u2013404S.","DOI":"10.1378\/chest.119.2_suppl.397S"},{"key":"key\n\t\t\t\t20171010182121_B2","doi-asserted-by":"crossref","unstructured":"Weinstein RA. Nosocomial infection update. Emerg Infect Dis1998; 4: 416\u201320.","DOI":"10.3201\/eid0403.980320"},{"key":"key\n\t\t\t\t20171010182121_B3","doi-asserted-by":"crossref","unstructured":"Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis2003; 1433\u20137.","DOI":"10.1086\/375081"},{"key":"key\n\t\t\t\t20171010182121_B4","doi-asserted-by":"crossref","unstructured":"Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother1999; 44: 19\u201323.","DOI":"10.1093\/jac\/44.suppl_1.19"},{"key":"key\n\t\t\t\t20171010182121_B5","doi-asserted-by":"crossref","unstructured":"Apfel CM, Locher H, Evers S et al. Peptide deformylase as an antibacterial drug target: target validation and resistance development. J Antimicrob Chemother2001; 45: 1058\u201364.","DOI":"10.1128\/AAC.45.4.1058-1064.2001"},{"key":"key\n\t\t\t\t20171010182121_B6","doi-asserted-by":"crossref","unstructured":"Huntington KM, Yi T, Wei Y et al. Synthesis and antibacterial activity of peptide deformylase inhibitors. Biochemistry2000; 39: 4543\u201351.","DOI":"10.1021\/bi992452y"},{"key":"key\n\t\t\t\t20171010182121_B7","doi-asserted-by":"crossref","unstructured":"Giglione C, Pierre M, Meinnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol2000; 36: 1197\u2013205.","DOI":"10.1046\/j.1365-2958.2000.01908.x"},{"key":"key\n\t\t\t\t20171010182121_B8","doi-asserted-by":"crossref","unstructured":"Apfel CM, Evers S, Hubschwerlen C et al. Peptide deformylase as an antibacterial drug target: assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells. Antimicrob Agents Chemother2001; 45: 1053\u20137.","DOI":"10.1128\/AAC.45.4.1053-1057.2001"},{"key":"key\n\t\t\t\t20171010182121_B9","doi-asserted-by":"crossref","unstructured":"Becker A, Schlichting I, Kabsch W et al. Structure of peptide deformylase and identification of the substrate binding site. J Biol Chem1998; 273: 11413\u20136.","DOI":"10.1074\/jbc.273.19.11413"},{"key":"key\n\t\t\t\t20171010182121_B10","doi-asserted-by":"crossref","unstructured":"Chen D, Hackbarth C, Ni ZJ et al. Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob Agents Chemother2004; 48: 250\u201361.","DOI":"10.1128\/AAC.48.1.250-261.2004"},{"key":"key\n\t\t\t\t20171010182121_B11","doi-asserted-by":"crossref","unstructured":"Smith KJ, Petit CM, Aubart K et al. Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species. Protein Sci2003; 12: 349\u201360.","DOI":"10.1110\/ps.0229303"},{"key":"key\n\t\t\t\t20171010182121_B12","doi-asserted-by":"crossref","unstructured":"Hao B, Gong W, Ravi Rajagopalan PT et al. Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry1999; 38: 4712\u20139.","DOI":"10.1021\/bi982594c"},{"key":"key\n\t\t\t\t20171010182121_B13","doi-asserted-by":"crossref","unstructured":"Fieulaine S, Juillan-Binard C, Serero A et al. The crystal structure of mitochondrial (type 1A) peptide deformylase provides clear guidelines for the design of inhibitors specific for the bacterial forms. J Biol Chem2005; 280: 4231\u201324.","DOI":"10.1074\/jbc.M507155200"},{"key":"key\n\t\t\t\t20171010182121_B14","doi-asserted-by":"crossref","unstructured":"Hackbarth CJ, Chen DZ, Lewis JG et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. J Antimicrob Chemother2002; 46: 2752\u201364.","DOI":"10.1128\/AAC.46.9.2752-2764.2002"},{"key":"key\n\t\t\t\t20171010182121_B15","doi-asserted-by":"crossref","unstructured":"Chen DZ, Patel DV, Hackbarth CJ et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry2000; 39: 1256\u201362.","DOI":"10.1021\/bi992245y"},{"key":"key\n\t\t\t\t20171010182121_B16","doi-asserted-by":"crossref","unstructured":"Jones RN, Rhomberg PR. Comparative spectrum and activity of NVP PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother2003; 51: 157\u201361.","DOI":"10.1093\/jac\/dkg055"},{"key":"key\n\t\t\t\t20171010182121_B17","doi-asserted-by":"crossref","unstructured":"Fritsche TR, Sader HS, Cleeland R et al. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob Agents Chemother2005; 49: 1468\u201376.","DOI":"10.1128\/AAC.49.4.1468-1476.2005"},{"key":"key\n\t\t\t\t20171010182121_B18","doi-asserted-by":"crossref","unstructured":"Anderegg TR, Jones RN, The Quality Control Working Group. Disk diffusion quality control guidelines for NVP PDF-713: a novel peptide deformylase inhibitor. Diagn Microbiol Infect Dis2004; 48: 55\u20137.","DOI":"10.1016\/S0732-8893(03)00162-7"},{"key":"key\n\t\t\t\t20171010182121_B19","doi-asserted-by":"crossref","unstructured":"Jones RN, Fritsche TR, Sader HS. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1837 recent Gram-positive clinical isolates. Diagn Microbiol Infect Dis2004; 49: 63\u20135.","DOI":"10.1016\/j.diagmicrobio.2003.12.005"},{"key":"key\n\t\t\t\t20171010182121_B20","doi-asserted-by":"crossref","unstructured":"Fritsche TR, Moet GJ, Jones RN. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM415), a novel inhibitor of bacterial peptide deformylase. Clin Microbiol Infect2004; 10: 843\u201360.","DOI":"10.1111\/j.1198-743X.2004.00946.x"},{"key":"key\n\t\t\t\t20171010182121_B21","doi-asserted-by":"crossref","unstructured":"Jones RN, Moet GJ, Sader HS et al. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J Antimicrob Chemother2004; 53: 804\u20137.","DOI":"10.1093\/jac\/dkh184"},{"key":"key\n\t\t\t\t20171010182121_B22","doi-asserted-by":"crossref","unstructured":"Credito K, Lin G, Ednie LM et al. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob Agents Chemother2004; 48: 4033\u20136.","DOI":"10.1128\/AAC.48.10.4033-4036.2004"},{"key":"key\n\t\t\t\t20171010182121_B23","doi-asserted-by":"crossref","unstructured":"Ednie LM, Pankuch G, Appelbaum PC. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob Agents Chemother2004; 48: 4027\u201332.","DOI":"10.1128\/AAC.48.10.4027-4032.2004"},{"key":"key\n\t\t\t\t20171010182121_B24","unstructured":"National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Document M7-A6. NCCLS, Wayne, PA, USA, 2003."},{"key":"key\n\t\t\t\t20171010182121_B25","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Document M100-S15. CLSI, Wayne, PA, USA, 2005."},{"key":"key\n\t\t\t\t20171010182121_B26","doi-asserted-by":"crossref","unstructured":"Jones RN, Sader HS, Fritsche TR. Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). Diagn Microbiol Infect Dis2005; 51: 139\u201341.","DOI":"10.1016\/j.diagmicrobio.2004.08.016"},{"key":"key\n\t\t\t\t20171010182121_B27","doi-asserted-by":"crossref","unstructured":"Margolis PS, Hackbarth CJ, Young DC et al. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother2000; 44: 1825\u201331.","DOI":"10.1128\/AAC.44.7.1825-1831.2000"},{"key":"key\n\t\t\t\t20171010182121_B28","doi-asserted-by":"crossref","unstructured":"Margolis PS, Hackbarth CJ, Lopez S et al. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob Agents Chemother2001; 45: 2432\u20135.","DOI":"10.1128\/AAC.45.9.2432-2435.2001"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/57\/5\/914\/2297779\/dkl093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T12:16:20Z","timestamp":1555503380000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/57\/5\/914\/764682\/Antimicrobial-activity-of-a-novel-peptide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,20]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2006,3,20]]},"published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkl093","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,5]]},"published":{"date-parts":[[2006,3,20]]}}}